#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Dabigatran in patients with diabetes mellitus and atrial fibrillation


Authors: Jakub Benko;  Veronika Mikušová;  Martin Jozef Péč;  Tomáš Bolek;  Matej Samoš;  Marián Mokáň
Authors‘ workplace: I. interná klinika JLF UK a UNM, Martin
Published in: Forum Diab 2022; 11(2): 82-86
Category:

Overview

Diabetes mellitus is associated with higher overall mortality and morbidity in patients with both atrial fibrillation and heart failure. One factor is the higher risk of stroke and systemic embolism. Therefore, consistent risk assessment and subsequent effective anticoagulant therapy in these patients is crucial. In the last decade, direct oral anticoagulants have come to the fore, which are gradually displacing warfarin from common practice. In our article, we summarize the existing information on the use of dabigatran specifically in patients with diabetes. We focus on the most important characteristics of this drug and emphasize some specifics within other drugs from the group of new anticoagulants – antidote idarucizumab, drug interactions and its use in patients with advanced chronic kidney disease.

Keywords:

stroke – Thromboembolism – anticoagulation therapy


Sources

1. Benjamin EJ, Levy D, Vaziri SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271(11): 840–844.

2. Krahn AD, Manfreda J, Tate RB et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98(5): 476–484. Dostupné zDOI: <http://dx.doi.org/10.1016/S0002–9343(99)80348–9>.

3. Gumprecht J, Lip GYH, Sokal A et al. Relationship between diabetes mellitus and atrial fibrillation prevalence in the Polish population: a report from the Non-invasive Monitoring for Early Detection of Atrial Fibrillation (NOMED-AF) prospective cross-sectional observational study. Cardiovasc Diabetol 2021; 20(1): 128. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–021–01318–2>.

4. Dahlqvist S, Rosengren A, Gudbjörnsdottir et al. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabetes Endocrinol 2017; 5(10): 799–807. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(17)30262–0>.

5. Lee Park K, Anter E. Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics J Atr Fibrillation 2013; 6(1): 751. Dostupné z DOI: <http://dx.doi.org/10.4022/jafib.751>.

6. Flint AC, Banki NM, Ren X et al. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke 2012; 43(10): 2788–2790. Dostupné z DOI: <http://dx.doi.org/10.1161/STROKEAHA.112.665844>.

7. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010 Nov 4;363(19):1877]. N Engl J Med 2009; 361(12): 1139–1151. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0905561>.

8. Brambatti M, Darius H, Oldgren J et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol 2015; 196: 127–131. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2015.05.141>.

9. Hsu CC, Hsu PF, Sung SH et al. Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban. Thromb Haemost 2018; 118(1): 72–81. Dostupné z DOI: <http://dx.doi.org/10.1160/TH17–02–0095>.

10. Lip GYH, Keshishian AV, Kang AL et al. Effectiveness and Safety of Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus. Mayo Clin Proc 2020; 95(5): 929–943. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mayocp.2019.05.032>.

11. Dam V, Dalmeijer GW, Vermeer C et al. Association Between Vitamin K and the Metabolic Syndrome: A 10-Year Follow-Up Study in Adults. J Clin Endocrinol Metab. 2015;100(6):2472–2479. Dostupné zDOI: <http://dx.doi.org/10.1210/jc.2014–4449>.

12. Yoshida M, Jacques PF, Meigs JB et al. Effect of vitamin K supplementation on insulin resistance in older men and women. Diabetes Care 2008; 31(11): 2092–2096. Dostupné z DOI: <http://dx.doi.org/10.2337/dc08–1204>.

13. Cheung CL, Sing CW, Lau WCY et al. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study. Cardiovasc Diabetol 2021; 20(1): 71. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–021–01263–0>.

14. Huang HK, Liu PP, Lin SM et al. Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study. Diabetes Obes Metab 2021; 23(2): 499–507. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14243>.

15. Reilly PA, Lehr T, Haertter S et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63(4): 321–328. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.07.104>.

16. Salmonson T, Dogné JM, Janssen H et al. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother 2017; 3(1): 42–47. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjcvp/pvw032>.

17. Samoš M, Bolek T, Stančiaková L et al. Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?. Diabetes Res Clin Pract 2018; 135: 172–177. Dostupné z DOI: <http://dx.doi.org/10.1016/j.diabres.2017.11.024>.

18. Steffel J, Collins R, Antz M et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021; 23(10): 1612–1676. Dostupné z DOI: <http://dx.doi.org/10.1093/europace/euab065>. Erratum in Corrigendum to: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Europace 2021; 23(10): 1676. Dostupné z DOI: <http://dx.doi.org/10.1093/europace/euab157>.

19. Pollack CV, Reilly PA, van Ryn J et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. N Engl J Med 2017; 377(5): 431–441. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1707278>.

20. Fanikos J, Murwin D, Gruenenfelder F et al. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. Thromb Haemost 2020; 120(1): 27–35. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0039–1695771>.

21. Stangier J, Rathgen K, Stähle H et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49(4): 259–268. Dostupné zDOI: <http://dx.doi.org/10.2165/11318170–000000000–00000>.

22. Blech S, Ebner T, Ludwig-Schwellinger E et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36(2): 386–399. Dostupné z DOI:<http://dx.doi.org/10.1124/dmd.107.019083>.

23. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol 2017; 12(12): 2032–2045. Dostupné z DOI: <http://dx.doi.org/10.2215/CJN.11491116>.

24. Stanifer JW, Pokorney SD, Chertow GM et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation 2020; 141(17): 1384–1392. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044059>.

25. Hindricks G, Potpara T, Dagres N et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Eur Heart J 2021; 42(5): 373–498. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaa612>. Erratum in Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42(5): 507. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehaa798>.

Labels
Diabetology Endocrinology Internal medicine
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#